266 related articles for article (PubMed ID: 9539769)
41. Defective antigen processing in GILT-free mice.
Maric M; Arunachalam B; Phan UT; Dong C; Garrett WS; Cannon KS; Alfonso C; Karlsson L; Flavell RA; Cresswell P
Science; 2001 Nov; 294(5545):1361-5. PubMed ID: 11701933
[TBL] [Abstract][Full Text] [Related]
42. Role of cathepsin D in antigen presentation of ovalbumin.
Rodriguez GM; Diment S
J Immunol; 1992 Nov; 149(9):2894-8. PubMed ID: 1328388
[TBL] [Abstract][Full Text] [Related]
43. Superantigen-presentation by rat major histocompatibility complex class II molecules RT1.Bl and RT1.Dl.
Dlaske H; Karaüzüm H; Monzon-Casanova E; Rudolf R; Starick L; Müller I; Wildner G; Diedrichs-Möhring M; Koch N; Miyoshi-Akiyama T; Uchiyama T; Wonigeit K; Fleischer B; Overbeck S; Rink L; Herrmann T
Immunology; 2009 Sep; 128(1 Suppl):e572-81. PubMed ID: 19740318
[TBL] [Abstract][Full Text] [Related]
44. MHC class II presentation of endogenous tumor antigen by cellular vaccines depends on the endocytic pathway but not H2-M.
Qi L; Ostrand-Rosenberg S
Traffic; 2000 Feb; 1(2):152-60. PubMed ID: 11208095
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of cathepsin S reduces allogeneic T cell priming but not graft-versus-host disease against minor histocompatibility antigens.
Fujii H; Ivison SM; Shimizu H; Kajiwara R; Kariminia A; Yan M; Dutz JP; Schultz KR
Biol Blood Marrow Transplant; 2012 Apr; 18(4):546-56. PubMed ID: 22178962
[TBL] [Abstract][Full Text] [Related]
46. Dynamics of major histocompatibility complex class II compartments during B cell receptor-mediated cell activation.
Lankar D; Vincent-Schneider H; Briken V; Yokozeki T; Raposo G; Bonnerot C
J Exp Med; 2002 Feb; 195(4):461-72. PubMed ID: 11854359
[TBL] [Abstract][Full Text] [Related]
47. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus.
Nakagawa T; Roth W; Wong P; Nelson A; Farr A; Deussing J; Villadangos JA; Ploegh H; Peters C; Rudensky AY
Science; 1998 Apr; 280(5362):450-3. PubMed ID: 9545226
[TBL] [Abstract][Full Text] [Related]
48. Excessive degradation of intracellular protein in macrophages prevents presentation in the context of major histocompatibility complex class II molecules.
Brazil MI; Weiss S; Stockinger B
Eur J Immunol; 1997 Jun; 27(6):1506-14. PubMed ID: 9209504
[TBL] [Abstract][Full Text] [Related]
49. Bacterial antigen delivery systems: phagocytic processing of bacterial antigens for MHC-I and MHC-II presentation to T cells.
Svensson M; Pfeifer J; Stockinger B; Wick MJ
Behring Inst Mitt; 1997 Feb; (98):197-211. PubMed ID: 9382741
[TBL] [Abstract][Full Text] [Related]
50. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice.
Nakagawa TY; Brissette WH; Lira PD; Griffiths RJ; Petrushova N; Stock J; McNeish JD; Eastman SE; Howard ED; Clarke SR; Rosloniec EF; Elliott EA; Rudensky AY
Immunity; 1999 Feb; 10(2):207-17. PubMed ID: 10072073
[TBL] [Abstract][Full Text] [Related]
51. Early endosomal maturation of MHC class II molecules independently of cysteine proteases and H-2DM.
Villadangos JA; Driessen C; Shi GP; Chapman HA; Ploegh HL
EMBO J; 2000 Mar; 19(5):882-91. PubMed ID: 10698930
[TBL] [Abstract][Full Text] [Related]
52. Protein degradation in MHC class II antigen presentation: opportunities for immunomodulation.
Medd PG; Chain BM
Semin Cell Dev Biol; 2000 Jun; 11(3):203-10. PubMed ID: 10906277
[TBL] [Abstract][Full Text] [Related]
53. Antigen presenting cells.
Hamilos DL
Immunol Res; 1989; 8(2):98-117. PubMed ID: 2659691
[TBL] [Abstract][Full Text] [Related]
54. Antigen processing by epidermal Langerhans cells correlates with the level of biosynthesis of major histocompatibility complex class II molecules and expression of invariant chain.
Puré E; Inaba K; Crowley MT; Tardelli L; Witmer-Pack MD; Ruberti G; Fathman G; Steinman RM
J Exp Med; 1990 Nov; 172(5):1459-69. PubMed ID: 2121888
[TBL] [Abstract][Full Text] [Related]
55. Presentation of arthritogenic peptide to antigen-specific T cells by fibroblast-like synoviocytes.
Tran CN; Davis MJ; Tesmer LA; Endres JL; Motyl CD; Smuda C; Somers EC; Chung KC; Urquhart AG; Lundy SK; Kovats S; Fox DA
Arthritis Rheum; 2007 May; 56(5):1497-506. PubMed ID: 17469112
[TBL] [Abstract][Full Text] [Related]
56. Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules.
Adams S; Humphreys RE
Eur J Immunol; 1995 Jun; 25(6):1693-702. PubMed ID: 7614997
[TBL] [Abstract][Full Text] [Related]
57. Trinitrophenol reactive T-cell hybridomas recognize antigens that require antigen processing.
Ma J; Wang JH; Sy MS; Guo YJ; Hauser C; Bigby M
J Invest Dermatol; 1994 Jul; 103(1):42-8. PubMed ID: 8027580
[TBL] [Abstract][Full Text] [Related]
58. Invariant chain processing is independent of cathepsin variation between primary human B cells/dendritic cells and B-lymphoblastoid cells.
Reich M; Zou F; Sieńczyk M; Oleksyszyn J; Boehm BO; Burster T
Cell Immunol; 2011; 269(2):96-103. PubMed ID: 21543057
[TBL] [Abstract][Full Text] [Related]
59. Inhibition by brefeldin A of presentation of exogenous protein antigens to MHC class II-restricted T cells.
Adorini L; Ullrich SJ; Appella E; Fuchs S
Nature; 1990 Jul; 346(6279):63-6. PubMed ID: 2366863
[TBL] [Abstract][Full Text] [Related]
60. Effective suppression of donor specific antibody production by Cathepsin S inhibitors in a mouse transplantation model.
Kubo K; Kawato Y; Nakamura K; Nakajima Y; Nakagawa TY; Hanaoka K; Oshima S; Fukahori H; Inami M; Morokata T; Higashi Y
Eur J Pharmacol; 2018 Nov; 838():145-152. PubMed ID: 30196110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
